Literature DB >> 19297049

High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL.

Madelon Pijls-Johannesma1, Ruud Houben, Liesbeth Boersma, Janneke Grutters, Katarina Seghers, Philippe Lambin, Rinus Wanders, Dirk De Ruysscher.   

Abstract

BACKGROUND AND
PURPOSE: Aggressive radiotherapy or concurrent chemo-radiation therapy for lung cancer leads to a high incidence of severe, mostly esophageal, toxicity. The purpose of this study was to investigate the evolution of quality of life (QoL) in patients with lung cancer, selected for curative radiotherapy (RT) or chemo-RT.
METHODS: Seventy-five lung cancer patients completed a longitudinal the EORTC QLQ-C30 and LC13. Linear mixed regression models were fitted to investigate the impact of different factors on overall QoL.
RESULTS: Overall QoL decreased shortly after the end of RT (4 points, p=0.19), but increased back to baseline within 3months. Mean scores of role functioning (p=0.018), cognitive functioning (p=0.002), dyspnoea (EORTC QLQ-LC13; p=0.043), dysphagia (p=0.005) and hoarseness (p=0.029), showed a significant worsening over time. Emotional functioning (p=0.033) improved significantly over time. Severe esophagitis (> or = grade 2) was reported in only 12% of the patients. Next to maximal esophageal toxicity > or = grade 2 (p=.0.010), also tumor stage IIIA (p<0.001), tumor stage IIIB (p=0.003), gender (p=0.042) and fatigue (p<0.001) appeared to be significant predictors of QoL.
CONCLUSION: High-dose radiotherapy or concurrent chemo-radiation in the treatment of lung cancer seems to be a well-tolerated treatment option with preservation of QoL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19297049     DOI: 10.1016/j.radonc.2009.02.010

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  12 in total

1.  Pulmonary artery invasion, high-dose radiation, and overall survival in patients with non-small cell lung cancer.

Authors:  Cheng-Bo Han; Wei-Li Wang; Leslie Quint; Jian-Xin Xue; Martha Matuszak; Randall Ten Haken; Feng-Ming Spring Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-28       Impact factor: 7.038

2.  Phenotypic and molecular characteristics associated with various domains of quality of life in oncology patients and their family caregivers.

Authors:  Kimberly E Alexander; Bruce A Cooper; Steven M Paul; Patsy Yates; Bradley E Aouizerat; Christine Miaskowski
Journal:  Qual Life Res       Date:  2016-05-09       Impact factor: 4.147

3.  Clinical significance of radiation dose-volume parameters and functional status on the patient-reported quality of life changes after thoracic radiotherapy for lung cancer: a prospective study.

Authors:  Byoung Hyuck Kim; Jin-Soo Kim; Ki Hwan Kim; Hyeon Jong Moon; Suzy Kim
Journal:  Radiol Med       Date:  2020-09-05       Impact factor: 3.469

Review 4.  [Results of N1 and N2 surgery in non-small cell lung cancer].

Authors:  J Pfannschmidt; J Kollmeier
Journal:  Chirurg       Date:  2019-12       Impact factor: 0.955

5.  Radiation-induced oesophagitis in lung cancer patients. Is susceptibility for neutropenia a risk factor?

Authors:  D De Ruysscher; J Van Meerbeeck; K Vandecasteele; C Oberije; M Pijls; A M C Dingemans; B Reymen; A van Baardwijk; R Wanders; G Lammering; P Lambin; W De Neve
Journal:  Strahlenther Onkol       Date:  2012-04-29       Impact factor: 3.621

6.  Health-related quality of life questionnaires in lung cancer trials: a systematic literature review.

Authors:  Kathrin Damm; Nicole Roeske; Christian Jacob
Journal:  Health Econ Rev       Date:  2013-05-16

Review 7.  Swallowing dysfunction in cancer patients.

Authors:  Judith E Raber-Durlacher; Mike T Brennan; Irma M Verdonck-de Leeuw; Rachel J Gibson; June G Eilers; Tuomas Waltimo; Casper P Bots; Marisol Michelet; Thomas P Sollecito; Tanya S Rouleau; Aniel Sewnaik; Rene-Jean Bensadoun; Monica C Fliedner; Sol Silverman; Fred K L Spijkervet
Journal:  Support Care Cancer       Date:  2011-12-29       Impact factor: 3.603

8.  Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy?

Authors:  Jie-Tao Ma; Li Sun; Xin Sun; Zhi-Cheng Xiong; Yang Liu; Shu-Ling Zhang; Le-Tian Huang; Cheng-Bo Han
Journal:  Radiat Oncol       Date:  2017-02-01       Impact factor: 3.481

9.  Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group.

Authors:  H H Strøm; R M Bremnes; S H Sundstrøm; N Helbekkmo; O Fløtten; U Aasebø
Journal:  Br J Cancer       Date:  2013-08-20       Impact factor: 7.640

10.  Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: a subset analysis from a randomized clinical phase III trial.

Authors:  Hans H Strøm; Roy M Bremnes; Stein H Sundstrøm; Nina Helbekkmo; Ulf Aasebø
Journal:  J Thorac Oncol       Date:  2014-06       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.